Should I buy or sell Cybin stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks .

What is Cybin's stock price target for 2024?

4 equities research analysts have issued twelve-month target prices for Cybin's stock. Their CYBN share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 919.2% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts .

How have CYBN shares performed in 2023?

Cybin's stock was trading at $0.3105 at the beginning of 2023. Since then, CYBN stock has increased by 34.3% and is now trading at $0.4170. View the best growth stocks for 2023 here .

Are investors shorting Cybin?

Cybin saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 12,400,000 shares, an increase of 15.1% from the October 31st total of 10,770,000 shares. Based on an average daily volume of 4,960,000 shares, the short-interest ratio is presently 2.5 days. Approximately 4.1% of the shares of the stock are short sold. View Cybin's Short Interest .

How were Cybin's earnings last quarter?

Cybin Inc. (NYSEAMERICAN:CYBN) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04).

Who are Cybin's major shareholders?

Cybin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (0.76%), Adviser Investments LLC (0.02%), Connecticut Wealth Management LLC (0.02%) and Thrive Wealth Management LLC (0.02%).

How do I buy shares of Cybin?

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cybin Stock Price, News & Analysis (NYSEAMERICAN:CYBN)

$0.42

-0.01 (-3.02%)

(As of 12:15 PM ET)

Compare

Today's Range: $0.41
▼
$0.43
50-Day Range: N/A
52-Week Range: $0.21
▼
$0.74

Volume: 1.16 million shs
Average Volume: 2.86 million shs
Market Capitalization: $169.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.25

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Cybin MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 919.2% Upside
$4.25 Price Target
Short Interest: Healthy
4.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.16) to ($0.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Cybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.25, Cybin has a forecasted upside of 919.2% from its current price of $0.42.
Amount of Analyst Coverage
Cybin has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.11% of the float of Cybin has been sold short.
Short Interest Ratio / Days to Cover
Cybin has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cybin has recently increased by 15.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cybin does not currently pay a dividend.
Dividend Growth
Cybin does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYBN.

2.4

News and Social Media Coverage

News Sentiment
Cybin has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cybin this week, compared to 1 article on an average week.
Search Interest
Only 16 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cybin insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.02% of the stock of Cybin is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cybin are expected to grow in the coming year, from ($0.16) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cybin is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cybin is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cybin has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cybin Stock (NYSEAMERICAN:CYBN)

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

CYBN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYBN Stock News Headlines

December 5, 2023 | finance.yahoo.com

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

November 16, 2023 | finance.yahoo.com

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 15, 2023 | finance.yahoo.com

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

November 14, 2023 | benzinga.com

Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin?

October 31, 2023 | finance.yahoo.com

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

October 31, 2023 | finance.yahoo.com

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023

October 25, 2023 | finance.yahoo.com

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 23, 2023 | msn.com

Psychedelic drug developer Cybin completes acquisition of Small Pharma

October 23, 2023 | finance.yahoo.com

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

October 13, 2023 | benzinga.com

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates

October 3, 2023 | benzinga.com

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

September 21, 2023 | finance.yahoo.com

Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

August 31, 2023 | msn.com

Psilocybin in depression: Study shows lasting benefit

August 28, 2023 | finance.yahoo.com

Canadian Investment Regulatory Organization Trade Resumption - CYBN

August 28, 2023 | finance.yahoo.com

Canadian Investment Regulatory Organization Trading Halt - CYBN

See More Headlines

Receive CYBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/07/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:CYBN
CUSIP: N/A
CIK: N/A
Web: www.cybin.com
Phone: 908-764-8385
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.25
High Stock Price Target: $5.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +888.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -105.10%
Return on Assets: -92.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.89
Quick Ratio: 2.89

Sales & Book Value

Annual Sales: $680,000.00
Price / Sales: 256.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 2.26

Miscellaneous

Outstanding Shares: 405,910,000
Free Float: 345,024,000
Market Cap: $174.54 million
Optionable: Not Optionable
Beta: 0.50

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Eric So L.L.B. (Age 47)
Co-Founder, President & Executive Chairman
Comp: $455.57k
Mr. Douglas L. Drysdale (Age 53)
Chief Executive Officer
Comp: $609.01k
Mr. Paul Glavine (Age 34)
Co-Founder, Chief Growth Officer & Director
Comp: $455.57k
Mr. Greg Cavers (Age 52)
Chief Financial Officer
Comp: $240.34k
Mr. Aaron Bartlone
Chief Operating Officer
Mr. John Kanakis (Age 43)
Co-Founder
Comp: $698.95k
Dr. Alex L. Nivorozhkin Ph.D. (Age 63)
Chief Scientific Officer
Ms. Lori Challenger
Chief Compliance, Ethics & Administrative Officer
Mr. Gabriel Fahel (Age 47)
Chief Legal Officer & Corporate Secretary
Sara Brittany Somerset
Chief Communications Officers

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CYBN Stock Analysis - Frequently Asked Questions

Should I buy or sell Cybin stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYBN shares.
View CYBN analyst ratings or view top-rated stocks.
What is Cybin's stock price target for 2024?: 4 equities research analysts have issued twelve-month target prices for Cybin's stock. Their CYBN share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 919.2% from the stock's current price.
View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts.
How have CYBN shares performed in 2023?: Cybin's stock was trading at $0.3105 at the beginning of 2023. Since then, CYBN stock has increased by 34.3% and is now trading at $0.4170.
View the best growth stocks for 2023 here.
Are investors shorting Cybin?: Cybin saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 12,400,000 shares, an increase of 15.1% from the October 31st total of 10,770,000 shares. Based on an average daily volume of 4,960,000 shares, the short-interest ratio is presently 2.5 days. Approximately 4.1% of the shares of the stock are short sold.
View Cybin's Short Interest.

How were Cybin's earnings last quarter?: Cybin Inc. (NYSEAMERICAN:CYBN) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04).
Who are Cybin's major shareholders?: Cybin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (0.76%), Adviser Investments LLC (0.02%), Connecticut Wealth Management LLC (0.02%) and Thrive Wealth Management LLC (0.02%).
How do I buy shares of Cybin?: Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:CYBN) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial